Get the Stockscreener App
92.77
2.12%
-2.01
Biontech Se Adr stock is traded at $92.77, with a volume of 607.23K.
It is down -2.12% in the last 24 hours and down -1.46% over the past month.
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates, or ADCs. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. Covid vaccine Comirnaty is its first commercialized product.
See More
Previous Close:
$94.78
Open:
$95.23
24h Volume:
607.23K
Relative Volume:
0.58
Market Cap:
$25.23B
Revenue:
$2.97B
Net Income/Loss:
$-812.83M
P/E Ratio:
-27.32
EPS:
-3.3962
Net Cash Flow:
$-1.24B
1W Performance:
-11.60%
1M Performance:
-1.46%
6M Performance:
-16.15%
1Y Performance:
+0.77%
1-Day Range:
$92.75
$96.30
1-Week Range:
$92.26
$106.99
52-Week Range:
$76.53
$131.49
Biontech Se Adr Stock (BNTX) Company Profile
Compare BNTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BNTX
Biontech Se Adr
|
92.77 | 25.23B | 2.97B | -812.83M | -1.24B | -3.3962 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Biontech Se Adr Stock (BNTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-13-25 | Initiated | Citigroup | Buy |
| Jan-10-25 | Initiated | Truist | Buy |
| Dec-11-24 | Initiated | Wells Fargo | Overweight |
| Dec-02-24 | Reiterated | BMO Capital Markets | Outperform |
| Nov-19-24 | Initiated | Berenberg | Buy |
| Nov-19-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Nov-08-24 | Upgrade | Goldman | Neutral → Buy |
| Sep-24-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-17-24 | Upgrade | Jefferies | Hold → Buy |
| Sep-16-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Aug-07-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Aug-02-24 | Upgrade | HSBC Securities | Hold → Buy |
| May-14-24 | Initiated | Evercore ISI | In-line |
| Feb-23-24 | Initiated | BMO Capital Markets | Outperform |
| Jan-05-24 | Initiated | Oppenheimer | Perform |
| Dec-01-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-16-23 | Downgrade | HSBC Securities | Buy → Hold |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-17-23 | Upgrade | Redburn | Neutral → Buy |
| Dec-15-22 | Upgrade | BofA Securities | Neutral → Buy |
| Aug-17-22 | Initiated | Cowen | Market Perform |
| Jul-13-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Jul-06-22 | Resumed | Canaccord Genuity | Buy |
| Feb-01-22 | Upgrade | Redburn | Sell → Neutral |
| Dec-16-21 | Initiated | Morgan Stanley | Equal-Weight |
| Nov-10-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-22-21 | Initiated | Deutsche Bank | Hold |
| Oct-07-21 | Initiated | Jefferies | Hold |
| Aug-11-21 | Upgrade | Bryan Garnier | Neutral → Buy |
| Jul-19-21 | Resumed | Wolfe Research | Outperform |
| Jun-16-21 | Downgrade | Redburn | Neutral → Sell |
| May-18-21 | Initiated | Goldman | Neutral |
| May-11-21 | Downgrade | Bryan Garnier | Buy → Neutral |
| Dec-01-20 | Downgrade | BofA Securities | Buy → Neutral |
| Aug-03-20 | Resumed | Berenberg | Buy |
| Jul-21-20 | Upgrade | BofA Securities | Neutral → Buy |
| Jun-30-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-19-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Apr-28-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Mar-18-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Mar-09-20 | Initiated | H.C. Wainwright | Neutral |
| Jan-24-20 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jan-22-20 | Downgrade | UBS | Buy → Neutral |
| Nov-05-19 | Initiated | Wolfe Research | Outperform |
| Nov-04-19 | Initiated | Berenberg | Buy |
| Nov-04-19 | Initiated | BofA/Merrill | Buy |
| Nov-04-19 | Initiated | Canaccord Genuity | Buy |
| Nov-04-19 | Initiated | JP Morgan | Overweight |
| Nov-04-19 | Initiated | SVB Leerink | Outperform |
| Nov-04-19 | Initiated | UBS | Buy |
View All
Biontech Se Adr Stock (BNTX) Latest News
Balance Sheet Breakdown: BioNTech SE ADR (BNTX)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - DWinneX
Why BioNTech Stock Got Trounced on Tuesday - The Motley Fool
Why BioNTech Stock Got Trounced On Tuesday - Barchart.com
BioNTech SE Reports Q1 2025 Financial Results - TipRanks
BioNTech’s Earnings Call: Oncology Progress Amid Financial Challenges - TipRanks
BioNTech SE ADR [NASDAQ: BNTX] Sees Increase in Stock Value - knoxdaily.com
HRL Shares Experience Surge in Value - knoxdaily.com
Nordson Corp [NDSN] stock for 268,620 USD was sold by Lovass Stephen - knoxdaily.com
Hanesbrands Inc [HBI] Records 200-Day SMA of $6.81 - knoxdaily.com
Ratio Review: Analyzing Regency Centers Corporation (REG)’s Price-to-Cash and Price-to-Free Cash Flow - DWinneX
Financial Metrics Exploration: Understanding MARA Holdings Inc (MARA) Through Ratios - DWinneX
Financial Fitness Check: Examining BioNTech SE ADR (BNTX)’s Key Ratios - DWinneX
The growth track for BioNTech SE ADR (BNTX) has changed recently - Sete News
Financial Health Report: Arthur J. Gallagher & Co (AJG)’s Ratios Tell a Tale - DWinneX
Financial Fitness Check: Examining B. Riley Financial Inc (RILY)’s Key Ratios - DWinneX
Pfizer Q1 Earnings Beat Estimates, Several Headwinds Hurt Sales - sharewise
A year in review: BioNTech SE ADR (BNTX)’s performance in the last year - uspostnews.com
BioNTech SE ADR (NASDAQ: BNTX) Could Make Significant Gains? - Marketing Sentinel
Investors Could Make -86.23% On NOV Inc (NYSE: NOV) Stock - Marketing Sentinel
Let’s Start With The Stock Forecast For UroGen Pharma Ltd (NASDAQ: URGN) - Marketing Sentinel
Is Murphy Oil Corp (NYSE: MUR) Stock Set To Rise More? - Marketing Sentinel
Why Is Summit Therapeutics Stock Trading Higher On Monday? - Benzinga
BioNTech SE ADR (BNTX) Stock: A Year of Market Fluctuations - investchronicle.com
Faraday Future Intelligent Electric Inc (FFAI) Stock: Exploring a Year of Highs, Lows, and Trading Volume - investchronicle.com
Community Health Systems, Inc Inc. (CYH) Price Performance: A Comparative Analysis with Competitors - investchronicle.com
Checking in on BioNTech SE ADR (BNTX) after recent insiders movement - knoxdaily.com
Will Pfizer's Non-COVID Drugs Drive Sales Again This Earnings Season? - Yahoo Finance
BioNTech SE ADR [BNTX] Shares Jump Approximately 32.28% Over the Year - knoxdaily.com
Today’s watch list includes BioNTech SE ADR (NASDAQ:BNTX) stock - uspostnews.com
AMKOR Technology Inc [AMKR] Records 200-Day SMA of $26.99 - knoxdaily.com
Fluence Energy Inc [FLNC] Officer makes an insider purchase of 78,258 shares worth 0.29 million. - knoxdaily.com
Immunovant Inc [IMVT] Records 50-Day SMA of $18.03 - knoxdaily.com
It makes sense and dollars to buy BioNTech SE ADR (BNTX) stock - Sete News
Novavax (NVAX) Surges 19.5%: Is This an Indication of Further Gains? - Yahoo Finance
BioNTech Surges On Summit's Coattails. But Can They Take On Merck? - Investor's Business Daily
Hewlett Packard Enterprise Co (HPE): What Are The Positives? - Marketing Sentinel
MARA Holdings Inc (MARA) Is A Buy Stock For Small Caps – Analysts - Marketing Sentinel
Stocks With Rising Relative Strength: BioNTech ADR - Investor's Business Daily
BioNTech, Pfizer report good news from vaccine trial - Morningstar
Century Aluminum Co [CENX] Stock sold by Insider Hoffman Robert F for $0.1 million - knoxdaily.com
Strength Seen in BioNTech (BNTX): Can Its 6.0% Jump Turn into More Strength? - Yahoo Finance
Zai Lab Limited (ZLAB) Moves 21.5% Higher: Will This Strength Last? - Yahoo Finance
Pfizer Stock Falls To New 52-Week Low: Should You Buy The Dip? - Barchart.com
CureVac’s amended patent upheld by European Patent Office - Investing.com
Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace
BioNTech’s Earnings Call: Oncology Growth Amidst Challenges - TipRanks
BioNTech’s 2024 Earnings Highlight Oncology Focus - TipRanks
BioNTech Earnings: 2025 Guidance Disappoints, Fair Value Lowered - Morningstar
BioNTech's mRNA Technology and Acquired Oncology Programs Could Support a Future Moat - Morningstar
Jefferies maintains BioNTech stock Buy rating, $149 target - Investing.com India
BioNTech Q4 earnings beat, but stock falls 3% on weak 2025 outlook - Investing.com
Biontech Se Adr Stock (BNTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.67%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):